Relugolix

Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used to treat several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States’ FDA in 2020, under the brand name Orgovyx, for the treatment of advanced prostate cancer. This branded product was later approved by the European Commission on April 29, 2022. Relugolix has also been studied in the symptomatic treatment of endometriosis. It is grouped under the following drug class(es): Antineoplastic agents and LHRH analogues. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Orgovyx, TAK-385 and Ryeqo. Its PubChem CID is 10348973.

CAS No 737789-87-6
Molecular Formula C29H27F2N7O5S
Molecular Weight 623.6 g/mol
Synonyms 1-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea

Frequently Asked Questions